FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?

by Anna Saborowski, Ulrich Lehmann, Arndt Vogel
Published 2020-09-01

Reply to Rizzo et al.

by Arndt Vogel, Javier Sanchez Alvarez, Monica Daigl, Philippe Merle
Published 2021-11-01

Adjuvant therapy of biliary tract cancers

by Joanna Kefas, John Bridgewater, Arndt Vogel, Alexander Stein, John Primrose
Published 2023-03-01

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

by Chiun Hsu, Lorenza Rimassa, Hui-Chuan Sun, Arndt Vogel, Ahmed O. Kaseb
Published 2021-07-01

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma

by Carolin Czauderna, Martha M. Kirstein, Hauke C. Tews, Arndt Vogel, Jens U. Marquardt
Published 2021-06-01

LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype.

by Sumadi Lukman Anwar, Britta Hasemeier, Elisa Schipper, Arndt Vogel, Hans Kreipe, Ulrich Lehmann
Published 2019-01-01

Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function

by Jasmine Huynh, May Thet Cho, Edward Jae-Hoon Kim, Min Ren, Zahra Ramji, Arndt Vogel
Published 2022-08-01

Next-Generation Biomarkers for Cholangiocarcinoma

by Pedro M. Rodrigues, Arndt Vogel, Marco Arrese, Domingo C. Balderramo, Juan W. Valle, Jesus M. Banales
Published 2021-06-01

Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review

by Arndt Vogel, Robin Kate Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Published 2023-01-01

Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma.

by Sumadi Lukman Anwar, Till Krech, Britta Hasemeier, Elisa Schipper, Nora Schweitzer, Arndt Vogel, Hans Kreipe, Ulrich Lehmann
Published 2012-01-01

The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective

by Brandon M. Meyers, Arndt Vogel, Paul Marotta, Petr Kavan, Laveena Kamboj, Janice Pan, Marc Geadah, David Trueman, Suthakar Sabapathy
Published 2021-01-01

Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE

by Davut B. Hasdemir, Lukas Aguirre Dávila, Nora Schweitzer, Bernhard C. Meyer, Armin Koch, Arndt Vogel, Frank Wacker, Thomas Rodt
Published 2017-05-01

Nrf2 Activates Augmenter of Liver Regeneration (ALR) via Antioxidant Response Element and Links Oxidative Stress to Liver Regeneration

by Rania Dayoub, Arndt Vogel, Jutta Schuett, Madeleine Lupke, Susannah M. Spieker, Nadja Kettern, Eberhard Hildt, Michael Melter, Thomas S. Weiss
Published 2013-07-01

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study

by Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Published 2024-02-01

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

by Jan Leipe, Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, Jessica C Hassel, Daniela Heller-Schenck, Matthias Pauschinger, Arndt Vogel, Lisa Zimmer, Ralf Gutzmer
Published 2019-06-01

Murine Embryonic Stem Cell-Derived Hepatic Progenitor Cells Engraft in Recipient Livers with Limited Capacity of Liver Tissue Formation

by Amar Deep Sharma, Tobias Cantz, Arndt Vogel, Axel Schambach, Dhivya Haridass, Markus Iken, Martina Bleidißel, Michael P. Manns, Hans R. Schöler, Michael Ott
Published 2008-03-01

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience

by Cornelia L. A. Dewald, Mia-Maria Warnke, Roland Brüning, Martin A. Schneider, Peter Wohlmuth, Jan B. Hinrichs, Anna Saborowski, Arndt Vogel, Frank K. Wacker
Published 2021-12-01

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave1...

by Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Published 2023-03-01

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in...

by Thorsten O. Goetze, Wolf O. Bechstein, Ulli Simone Bankstahl, Tobias Keck, Alfred Königsrainer, Sven A. Lang, Claudia Pauligk, Pompiliu Piso, Arndt Vogel, Salah-Eddin Al-Batran
Published 2020-02-01

Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT

by Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Published 2024-02-01